Table 2 Comparison of clinical characteristics and EEG abnormalities in clozapine-treated patients
Variables | With EEG abnormalities (N = 65) | Without EEG abnormalities (N = 42) | t/k2 | p-value |
|---|---|---|---|---|
Age, mean ± SD | 38.35 ± 0.82 | 38.43 ± 1.23 | 0.05 | 0.96 |
Gender, n (%) | 1.36 | 0.24 | ||
Male | 50 (64.10) | 28 (35.90) | ||
Female | 15 (51.72) | 14 (48.28) | ||
Duration of illness (years), mean ± SD | 9.66 ± 0.58 | 9.57 ± 0.88 | − 0.09 | 0.93 |
Dose of clozapine, mean ± SD | 385 ± 7.86 | 289.29 ± 5.60 | − 8.88 | < 0.01* |
Duration on clozapine (weeks), mean ± SD | 14.57 ± 7.09 | 12.71 ± 5.99 | 1.40 | 0.164 |
Smoking, n (%) | 0.90 | 0.41 | ||
Yes | 39 (57.35) | 29 (42.65) | ||
No | 26 (66.67) | 13 (33.33) | ||
Diagnosis, n (%) | 1.18 | 0.55 | ||
Schizophrenia | 51 (62.96) | 30 (37.04) | ||
Schizoaffective disorder | 12 (57.14) | 9 (42.86) | ||
Bipolar disorder | 2 (40) | 3 (60) | ||
Total: 107 | ||||